
Danaher (DHR) Stock Forecast & Price Target
Danaher (DHR) Analyst Ratings
Bulls say
Danaher has undergone a strategic transformation from a real estate organization to a focused industrial manufacturer, particularly within the life science and diagnostic sectors. Recent trends indicate a resurgence in biotech approvals and steady growth in gene and cell therapy activities, which are expected to positively influence Danaher's commercial operations, especially within its Cytiva business that benefits from on-market products. With strong sequential order growth observed in the biotech segment and a projected EPS acceleration towards $9 by FY26, financial indicators suggest a favorable outlook for Danaher's future performance.
Bears say
Danaher's financial outlook appears negative due to several key factors impacting its revenue projections and market environment. The company's FY'25 revenue guidance of +3% organic growth falls approximately 200 basis points short of analysts' expectations, primarily driven by a projected $300 million decline in respiratory sales and $100 million in pricing challenges within the China diagnostics business. Moreover, external risks, including the potential impact of U.S. and international regulatory changes, decreased spending in biopharmaceuticals, and uncertainty surrounding academic funding, further compound the outlook for Danaher's financial performance.
This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.
Danaher (DHR) Analyst Forecast & Price Prediction
Start investing in Danaher (DHR)
Order type
Buy in
Order amount
Est. shares
0 shares